These include primarily CARD11, affected by point mutations in ~9% of ABC-DLBCL, and >15% of MCD-DLBCL cases, but also BCL10 (mostly copy number gains in 5-10% of cases, preferentially in BN2/C1-DLBCL) and MALT1 (<5% of cases). This evidence concerns the gene MALT1 and diffuse large B-cell lymphoma.